The cost of hospital care for HIV patients in Colombia: an insurer’s perspective
| Autor: | Abel E González-Vélez, Javier A García-Buitrago, Mario A. Isaza-Ruget, Karen L Rincón-Ramírez, Paola A Rengifo-Bobadilla, Carlos A Álvarez-Moreno, Claudia Carolina Colmenares-Mejía |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Cost-Benefit Analysis Insurance Carriers HIV Infections Dermatology Disease Colombia 03 medical and health sciences 0302 clinical medicine Exchange rate Cost of Illness Acquired immunodeficiency syndrome (AIDS) Environmental health Humans Medicine Pharmacology (medical) In patient Consumer price index 030212 general & internal medicine health care economics and organizations AIDS-Related Opportunistic Infections business.industry 030503 health policy & services Public Health Environmental and Occupational Health Health Care Costs Middle Aged medicine.disease Hospital care Hospitalization Social security Infectious Diseases Costs and Cost Analysis Hiv patients Female 0305 other medical science business |
| Zdroj: | International Journal of STD & AIDS. 30:696-702 |
| ISSN: | 1758-1052 0956-4624 |
| DOI: | 10.1177/0956462419835636 |
| Popis: | The aim of this study was to evaluate the cost derived from the hospitalization of people living with HIV (PLHIV) in Colombia between 2011 and 2015. This is an analysis of the direct cost of PLHIV hospitalization from the perspective of an insurer of the Colombian General Social Security System. The costs were calculated in Colombian pesos and corrected for inflation on the basis of the 2017 Consumer Price Index of the Bank of the Republic of Colombia. It was converted to US dollars at the Market Representative Exchange Rate of the same year. We analyzed 1129 hospitalizations in 612 PLHIV, of which 12% started with a diagnosis of HIV during the same hospitalization, with the majority in the AIDS stage (63%). The median overall cost of hospitalizations was US$1509 (25th and 75th percentiles: US$711–US$3254), being even higher in patients with AIDS and as the CD4 T lymphocyte count decreased. The cost derived from the medical care of PLHIV increases as the clinical control of the disease worsens, and it is a key indicator of the impact of the strategies implemented for the timely identification of the infection and subsequent management of the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|